


**Amendments to the Claims**


This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently amended) A **pharmaceutical composition comprising a protein kinase inhibitor composition comprising a** compound having the chemical formula:



wherein R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> is each independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, OH, amine, thioether, SH, halogen, hydrogen, NO<sub>2</sub> and NH<sub>2</sub>; and R<sub>5</sub> is an alkylaryl comprising an alkyl group and an aryl group having the following structure:




wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, and X<sub>5</sub> is each independently selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, and NO<sub>2</sub>;

**and a physiologically acceptable carrier.**

2. (Currently amended) The composition of claim 1, wherein R<sub>1</sub> and R<sub>2</sub> **[[and]] are** OH, and R<sub>3</sub> is hydrogen.


3. (Cancelled)

4. (Currently amended) The composition of claim 1, wherein said compound is **[[M13]]**




Claims 5-31 (Cancelled)

32. (Previously presented) A method of treating a patient having a cell proliferation disorder by administering to said patient a therapeutically effective amount of a compound of the formula:



wherein R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> is each independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, OH, amine, thioether, SH, halogen, hydrogen, NO<sub>2</sub> and NH<sub>2</sub>; and

R<sub>5</sub> is an alkylaryl comprising an alkyl group and an aryl group having the following structure:



wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, and X<sub>5</sub> is each independently selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, and NO<sub>2</sub>.

Claims 33-35 (Cancelled)

36. (Currently amended) The method of claim [[30]] 32, wherein said disorder is characterized by inappropriate activity of EGF-R.

37. (Currently amended) The method of claim [[31]] 32, wherein said cell proliferative disorder is a cancer.

38. (Original) The method of claim 37, wherein said cancer is selected from the group consisting of breast carcinomas, stomach adenocarcinomas, salivary gland adenocarcinomas, endometrial cancers, ovarian adenocarcinomas, gastric cancers, colorectal cancers, and glioblastomas.


39. (Original) The method of claim 38, wherein said cancer is breast cancer.

Claims 40-43 (Cancelled)

44. (Previously presented) The composition of claim 1, wherein R<sub>1</sub> and R<sub>3</sub> are isopropyl and R<sub>2</sub> is hydroxy.

45. (Previously presented) The composition of claim 44, further comprising a physiologically acceptable carrier.


46. (Currently amended) The composition of claim 1, wherein said compound is [[M24]]



47. (Previously presented) The method of claim 32, wherein R<sub>1</sub> and R<sub>2</sub> are OH and R<sub>3</sub> is hydroxy.

48. (Previously presented) The method of claim 32, further comprising a physiologically acceptable carrier.


49. (Currently amended) The method of claim 32, wherein said compound is [[M13]]



50. (Previously presented) The method of claim 32, wherein R<sub>1</sub> and R<sub>3</sub> are isopropyl and R<sub>2</sub> is hydroxy.

51. (Currently amended) The method of claim 32, wherein the compound is administered with further comprising a physiologically acceptable carrier.

52. (Currently amended) The method of claim 32, wherein said compound is [[M24]]



53. (Previously presented) A method of treating a patient having a cancer characterized by over-activity of HER2, wherein said cancer is sensitive to treatment by a compound of either claim 1 or claim 32, comprising administering to said patient a therapeutically effective amount of a compound of either claim 1 or claim 32.

54. (Previously presented) A method of treating a patient having a cancer characterized by inappropriate activity of EGFR, wherein said cancer is sensitive to treatment by a compound of either claim 1 or claim 32, comprising administering to said patient a therapeutically effective amount of a compound of either claim 1 or claim 32.